CTOs on the Move

MOMA Therapeutics

www.momatx.com

 
We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.momatx.com
  • 215 First Street Suite 150
    Cambridge, MA USA 02140
  • Phone: 617.936.0384

Executives

Name Title Contact Details

Funding

MOMA Therapeutics raised $86M on 04/16/2020
MOMA Therapeutics raised $150M on 05/10/2022

Similar Companies

Hawaii Bioenergy

Hawaii Bioenergy is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.

Prelude Therapeutics

Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases